Horizon Therapeutics Presents Phase 3 Study Results Identifying Risk Factors for Ulcer Development Among NSAID Users
10/26/2009 9:09:26 AM
More...
|
Horizon Therapeutics Names Dr. Jeffrey W. Sherman Executive Vice President and Chief Medical Officer
6/30/2009 9:45:07 AM
More...
|
Horizon Therapeutics' HZT-501 Significantly Reduces Incidence of NSAID-Induced Upper Gastrointestinal Ulcers in Patients With Mild-to-Moderate Pain
6/2/2009 8:53:38 AM
More...
|
Horizon Therapeutics Selected to Present at InsideVenture's Debut Investor Conference March 25-26, Santa Barbara, California
3/23/2009 11:50:13 AM
More...
|
Horizon Therapeutics Announces Senior Management Appointments
1/6/2009 11:23:36 AM
More...
|
Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints
12/2/2008 9:29:34 AM
More...
|
Horizon Therapeutics Names Robert J. De Vaere Executive Vice President and Chief Financial Officer
10/9/2008 8:32:05 AM
More...
|
Horizon Therapeutics Announces Corporate Relocation to the Chicago Area
7/31/2008 9:28:35 AM
More...
|
Horizon Therapeutics Names Timothy P. Walbert as President and CEO
7/24/2008 7:17:25 AM
More...
|
Horizon Therapeutics Completes Enrollment in Phase 3 Trials for Lead Product Candidate HZT-501
2/11/2008 7:38:17 AM
More...
|
|